Showing 7011-7020 of 8896 results for "".
- Business News: LEO Pharma to Acquire Timber Pharmaceuticalshttps://practicaldermatology.com/news/business-news-leo-pharma-to-acquire-timber-pharmaceuticals/2461943/LEO Pharma is set to acquire Timber Pharmaceuticals, Inc. The deal represents a total transaction value of up to $36 million with an initial upfront consideration of $14 million, and up to an additional $22.0 million in contingent value rights payable upon achievement o
- La Roche-Posay Is the Official Sunscreen of the US Open for the Second Yearhttps://practicaldermatology.com/news/la-roche-posay-is-the-official-sunscreen-of-the-us-open-for-the-second-year/2461941/La Roche-Posay is continuing its partnership as the exclusive Official Sunscreen Partner of the US Open for the second year in a row. At the 2022 US Open, La Roche-Posay provided access to board-certified dermatologists to educate on sun safety and distributed 300,000 free sunscree
- First Patient Dosed in Phase 1/2a Trial of AGLE-102 to Treat Severe Second-degree Burnshttps://practicaldermatology.com/news/first-patient-dosed-in-phase-12a-trial-of-agle-102-to-treat-severe-second-degree-burns/2461938/The first patient has been dosed in Aegle Therapeutics Corp.’s Phase 1/2a clinical trial of AGLE-102 for the treatment of severe second-degree burns. AGLE-102 is an investigational product comprised of native extracellular vesicles isolated from allogeneic stem cel
- Inmagene's OX40 mAb Enters POC Study in ADhttps://practicaldermatology.com/news/inmagenes-ox40-mab-enters-poc-study-in-ad/2461934/The first patient has been dosed in a global multicenter proof-of-concept (POC) study of Inmagene Biopharmaceuticals’ IMG-007 in adults with moderate-to-severe atopic dermatitis (AD). The objective of the study is to assess the safety, pharmacokinetics, and efficacy of
- Found: 135 New Melanin Genes Responsible for Pigmentationhttps://practicaldermatology.com/news/found-135-new-melanin-genes-responsible-for-pigmentation/2461927/Researchers have discovered 135 new genes associated with pigmentation. “To understand what actually causes different amounts of melanin to be produced, we used a technology called CRISPR-Cas9 to genetically engineer cells,” explains study author
- The Dermatology Practice of the Future: AI-Powered Piction Health Dermatology Launches in Massachusettshttps://practicaldermatology.com/news/the-dermatology-practice-of-the-future-ai-powered-piction-health-dermatology-launches-in-mass/2461923/Piction Health Dermatology, an AI-enabled dermatology virtual clinic, is now open for Massachusetts residents. Piction's virtual clinic merges artificial intelligence (AI) with the expertise of board-certified dermatologists. Patients complete a short medical in
- UF Researcher Recognized for Life’s Work on Neurofibromatosishttps://practicaldermatology.com/news/uf-researcher-recognized-for-lifes-work-on-neurofibromatosis/2461922/Margaret “Peggy” Wallace, PhD, a professor in the department of molecular genetics and microbiology in the University of Florida College of Medicine, has received an award from the Children’s Tumor Foundation in recognition of her significant contributions to neurofibromatosis r
- Study: Natural Gas Odorants Linked to Skin Rasheshttps://practicaldermatology.com/news/study-natural-gas-odorants-linked-to-skin-rashes/2461918/Odorants are widely used in natural gas for leak detection and may induce a range of adverse health symptoms at very low concentrations including skin rashes, according to a new study in Current Environm
- PSA: Vets Warn That Minoxidil May Be Deadly to Petshttps://practicaldermatology.com/news/vets-warn-that-minoxidil-may-be-deadly-to-pets/2461917/Products like Rogaine, which contain minoxidil, can be very dangerous to animals, warn toxicology experts at Pet Poison Helpline. “Cats are particularly sensitive to this medication, and any exposure can result in severe poisoning and potentially death,” says Renee
- Positive Topline Data Seen in Phase II Trial of LNK01001 in ADhttps://practicaldermatology.com/news/positive-topline-data-seen-in-phase-ii-trial-of-lnk01001-in-ad/2461916/Lynk Pharmaceuticals Co., Ltd.’s LNK01001 performed well in a Phase II clinical trial for the treatment of atopic dermatitis (AD), according to positive topline data from the Company. LNK01001 is a highly selective JAK1 inhibitor that blocks JAK1 without crossing over onto ot